Klaus Metzeler, MD, of LMU Hospital Munich, Munich, Germany, discusses his group’s work on the genotyping and single cell RNA sequencing of acute myeloid leukemia (AML) patients with subclonal mutations, with the long-term aim of identifying novel therapeutic targets and better understanding the disease. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.